FBRX
vs
S&P 500
FBRX
S&P 500
Over the past 12 months, FBRX has significantly outperformed S&P 500, delivering a return of +384% compared to the S&P 500's +18% growth.
Stocks Performance
FBRX vs S&P 500
Performance Gap
FBRX vs S&P 500
Performance By Year
FBRX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Forte Biosciences Inc
Glance View
Forte Biosciences, Inc. is a clinical stage biopharmaceutical company focused on dermatology. The company is headquartered in Torrance, California and currently employs 5 full-time employees. The company went IPO on 2017-04-13. The firm is focused on its lead product candidate, FB-401, which is a topical live biotherapeutic for the treatment of inflammatory skin diseases, including pediatric and adult patients with atopic dermatitis (AD). FB401 was developed in collaboration with the National Institutes of Health (NIH), and the National Institute of Allergy and Infectious Diseases (NIAID). FB-401 has completed Phase I/II a testing in adult and pediatric patients with atopic dermatitis.
